Latest News

Since its establishment, Sartorius Stedim Biotech has expanded the site through investments in infrastructure, production capacity, and employee training.

Through the partnership, PureHealth and Erth Hospitality will apply hospitality practices to non-clinical aspects of the hospital environment.

Seven countries, which include Angola, Bangladesh, the Democratic Republic of the Congo, Nigeria, South Sudan, Sudan and Yemen, accounted for about 90% of reported cases and deaths.

D-dimer testing measures fragments produced when blood clots break down and can help assess patients with increased clotting activity.

TLB 33 is a human immunoglobulin G1 monoclonal antibody designed to bind to and neutralise interleukin 33, an immune signalling protein.

The Danish pharmaceutical company will receive exclusive rights to develop, manufacture and commercialise HRS-1596 outside mainland China, Hong Kong, Macau and Taiwan.

The deal comes as pharmaceutical companies increase investment in therapies that target RAS, a family of proteins involved in regulating cell growth and division.

The companies have also signed a non-binding MoU covering a broader global programme to evaluate ivonescimab in combination with additional AstraZeneca oncology therapies.

The development of Accela and NeoArc involved collaboration with an advisory group comprising several cancer research and treatment institutions.

Merck plans to present the BRUNELLO results at the American Academy of Ophthalmology Annual Meeting in New Orleans on October 10 and discuss the findings with regulatory authorities.